Compare Bristol-Myers Squibb Co (BMY) vs C.H. Robinson Worldwide, Inc. (CHRW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs C.H. Robinson Worldwide, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.74 (market cap $129.94B), while C.H. Robinson Worldwide, Inc. trades at $147.96 (market cap $16.96B). The key difference: Bristol-Myers Squibb Co is far larger — about 7.7× C.H. Robinson Worldwide, Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | CHRW | |
|---|---|---|
Market Cap | $129.94B | $16.96B |
Sector | Health | Industrials |
52-Week High | $65.89 | $209.42 |
52-Week Low | $42.60 | $118.77 |
Enterprise Value | $163.92B | $18.78B |
Dividend Yield | 3.96% | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
CHRW trades at $147.68, down 0.41% with bearish technical signals, though recent earnings beats and strong profitability metrics provide fundamental support. The company reported Q2 2026 EPS of $1.61, beating expectations, with revenue of $16.23B in 2025 and net income margin improving to 3.73%. Analyst consensus remains positive with a $193 price target, while recent news highlights dividend declarations and institutional buying activity.
Outlook remains cautiously optimistic given earnings momentum and solid ROE of 37.12%, though technical weakness and legal challenges pose near-term risks. The stock offers growth potential with reasonable valuation (P/E 27.7) but faces headwinds from freight demand volatility and competitive pressures in logistics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About C.H. Robinson Worldwide, Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →
